公开(公告)号：US20180215764A1

公开(公告)日：2018-08-02

申请号：US15852179

申请日：2017-12-22

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Andrew Burchat ,  Justin D. Dietrich ,  Michael Friedman ,  David Ihle ,  David Kinsman ,  Kelly Mullen ,  Augustine T. Osuma ,  Anil Vasudevan ,  Noel S. Wilson

IPC: C07D487/04 ,  C07D519/00 ,  C07D498/04

CPC classification number: C07D487/04 ,  C07D498/04 ,  C07D519/00

Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

公开(公告)号：US09957274B2

公开(公告)日：2018-05-01

申请号：US15588398

申请日：2017-05-05

Applicant: AbbVie Inc.

Inventor： Michael R. Michaelides ,  Michael L. Curtin ,  Huan-Qiu Li ,  Marina A Pliushchev ,  Ying Wang ,  Hongyu H. Zhao ,  Richard F. Clark ,  Alan S. Florjancic ,  Zhiqin Ji ,  Mariazel Torrent ,  Ramzi F. Sweis ,  Anil Vasudevan ,  Justin D. Dietrich

IPC: C07D207/14 ,  A61K31/40 ,  C07D487/04 ,  C07D403/10 ,  C07D405/04 ,  C07D413/10 ,  C07D403/12 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04 ,  C07D401/04 ,  C07D401/14

CPC classification number: C07D487/04 ,  A61K31/40 ,  C07D207/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D413/10 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US09856253B2

公开(公告)日：2018-01-02

申请号：US15130362

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton Longenecker ,  Augustine Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel Wilson

IPC: C07D227/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20170173009A1

公开(公告)日：2017-06-22

申请号：US15449565

申请日：2017-03-03

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Wilhelm Amberg ,  Frauke Pohlki ,  Udo Lange ,  Ying Wang ,  Jason Brewer ,  Anil Vasudevan ,  Yanbin Lao ,  Charles Hutchins ,  Hongyu Zhao ,  Huan-Qiu Li

IPC: A61K31/501 ,  A61K31/4433 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4178 ,  A61K31/397

Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

公开(公告)号：US09550754B2

公开(公告)日：2017-01-24

申请号：US14849470

申请日：2015-09-09

Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

Inventor： Wilhelm Amberg ,  Jason Brewer ,  Charles Hutchins ,  Udo Lange ,  Yanbin Lao ,  Huan-Qiu Li ,  Frauke Pohlki ,  Anil Vasudevan ,  Ying Wang ,  Hongyu Zhao

IPC: C07D403/12 ,  C07D401/14

CPC classification number: C07D403/12 ,  C07D401/14

Abstract: The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole derivatives, and the use of such 4,5-dihydropyrazole derivatives for therapeutic purposes.

Abstract translation: 本发明涉及式（I）的4,5-二氢吡唑衍生物及其生理学上耐受的盐，它们是GlyT1抑制剂。 本发明还涉及包含这种4,5-二氢吡唑衍生物的药物组合物，以及这些用于治疗目的的这种4,5-二氢吡唑衍生物的用途。

公开(公告)号：US20160031880A1

公开(公告)日：2016-02-04

申请号：US14880834

申请日：2015-10-12

Applicant: AbbVie Inc.

Inventor： Rick F. Clark ,  Michael L. Curtain ,  Todd M. Hansen ,  Howard R. Heyman ,  Helmut Mack ,  Michael Michaelides ,  Marina A. Pliushchev ,  Omar J. Shah ,  Bryan K. Sorensen ,  Ramzi Sweis ,  Chris Tse ,  Anil Vasudevan ,  Kevin R. Woller

IPC: C07D471/04 ,  A61K31/496 ,  A61K31/506 ,  C07D519/00 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/437 ,  A61K31/501

CPC classification number: C07D209/44 ,  A61K31/437 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D407/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

Abstract translation: 公开了抑制NAMPT活性的化合物，含有该化合物的组合物和治疗其中NAMPT表达的疾病的方法。 公开了抑制ROCK活性的化合物，含有化合物的组合物和治疗ROCK表达疾病的方法。

公开(公告)号：US20150111867A1

公开(公告)日：2015-04-23

申请号：US14517034

申请日：2014-10-17

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Wilhelm Amberg ,  Frauke Pohlki ,  Udo Lange ,  Ying Wang ,  Jason Brewer ,  Anil Vasudevan ,  Yanbin Lao ,  Charles Hutchins ,  Hongyu Zhao ,  Huan-Qiu Li

IPC: C07D405/14 ,  C07D405/04

CPC classification number: A61K31/501 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4433 ,  C07D311/58 ,  C07D405/04 ,  C07D405/14

Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereofThe invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

Abstract translation: 本发明涉及式（I）的氨基苯并二氢吡喃，氨基硫色烷和氨基-1,2,3,4-四氢喹啉衍生物或其生理上可耐受的盐。本发明涉及包含这种氨基苯并二氢吡喃，氨基硫色烷和氨基-1,2 ，3,4-四氢喹啉衍生物，以及用于治疗目的的这种氨基苯并二氢吡喃，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物的用途。 氨基苯并二氢吡喃，氨基硫色烷和氨基-1,2,3,4-四氢喹啉衍生物是GlyT1抑制剂。

公开(公告)号：US10233179B2

公开(公告)日：2019-03-19

申请号：US14786454

申请日：2014-04-22

Applicant: AbbVie Inc.

Inventor： Iok Chan Ng ,  M-akhteruzzaman Molla ,  Tami J. Pilot-Matias ,  Anil Vasudevan ,  Tatyana Dekhtyar ,  Artour Gomtsian ,  Kathy Sarris ,  Ana Aguirre ,  Mikhail Chafeev

IPC: C07D417/14 ,  C07D403/14 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：US09879016B2

公开(公告)日：2018-01-30

申请号：US15130323

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Eric Breinlinger ,  Andrew Burchat ,  Justin Dietrich ,  Michael Friedman ,  David Ihle ,  David Kinsman ,  Kelly Mullen ,  Augustine Osuma ,  Anil Vasudevan ,  Noel Wilson

IPC: C07D487/04 ,  C07D498/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D498/04 ,  C07D519/00

Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

公开(公告)号：US20170253562A1

公开(公告)日：2017-09-07

申请号：US15287851

申请日：2016-10-07

Applicant: AbbVie Inc.

Inventor： Michael L. Curtin ,  Anil Vasudevan ,  Kevin Woller

IPC: C07D209/44 ,  C07D403/12 ,  C07D405/12 ,  C07D491/10 ,  A61K31/55 ,  A61K31/547 ,  A61K31/5377 ,  A61K31/501 ,  C07D491/107 ,  C07D491/048 ,  C07D487/04 ,  A61K31/551 ,  A61K31/4035 ,  A61K31/4178

CPC classification number: C07D209/44 ,  A61K31/4035 ,  A61K31/4178 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K45/06 ,  C07D403/12 ,  C07D405/12 ,  C07D487/04 ,  C07D491/048 ,  C07D491/10 ,  C07D491/107 ,  A61K2300/00

Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.